Lite Strategy, Inc. (formerly MEI Pharma, Inc.) is a pharmaceutical company developing novel cancer therapies, with drug candidates voruciclib (oral CDK9 inhibitor) and zandelisib (oral PI3K inhibitor). In August 2025, following a $100 million PIPE, the company implemented a Litecoin Treasury Strategy by acquiring Litecoin (LTC) tokens as its primary reserve asset, while continuing to assess pre-clinical drug development activities.
Q2 FY2026 — expected 2026-09-12
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-09-26 | 2025-06-30 | 0001193125-25-220421 | EDGAR | 65K words |
| 2024-09-19 | 2024-06-30 | 0000950170-24-108185 | EDGAR | — |
| 2023-09-26 | 2023-06-30 | 0000950170-23-049927 | EDGAR | — |
| 2022-09-08 | 2022-06-30 | 0000950170-22-018236 | EDGAR | — |
| 2021-09-02 | 2021-06-30 | 0000950170-21-001655 | EDGAR | — |
| 2020-09-09 | 2020-06-30 | 0001193125-20-242169 | EDGAR | — |
| 2019-08-28 | 2019-06-30 | 0001193125-19-232454 | EDGAR | — |
| 2018-08-30 | 2018-06-30 | 0001193125-18-263586 | EDGAR | — |
| 2017-09-05 | 2017-06-30 | 0001193125-17-276135 | EDGAR | — |
| 2016-09-06 | 2016-06-30 | 0001193125-16-701415 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-17 | 2025-12-31 | 0001193125-26-053215 | EDGAR | 27K words |
| 2025-11-14 | 2025-09-30 | 0001193125-25-283111 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0000950170-25-070276 | EDGAR | — |
| 2025-02-12 | 2024-12-31 | 0000950170-25-018809 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0000950170-24-125328 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0000950170-24-056834 | EDGAR | — |
| 2024-02-13 | 2023-12-31 | 0000950170-24-014640 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0000950170-23-061976 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0000950170-23-021179 | EDGAR | — |
| 2023-02-09 | 2022-12-31 | 0000950170-23-002323 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0000950170-22-024967 | EDGAR | — |
| 2022-05-23 | 2022-03-31 | 0000950170-22-010498 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-17 | 0001193125-26-053243 | EDGAR | 1K words |
| 2026-02-12 | 0001193125-26-049005 | EDGAR | — |
| 2025-12-30 | 0001193125-25-335761 | EDGAR | — |
| 2025-12-05 | 0001193125-25-309593 | EDGAR | — |
| 2025-11-18 | 0001193125-25-286424 | EDGAR | — |
| 2025-10-30 | 0001193125-25-258474 | EDGAR | — |
| 2025-09-15 | 0001193125-25-203520 | EDGAR | — |
| 2025-09-10 | 0001262104-25-000009 | EDGAR | — |
| 2025-09-04 | 0000929638-25-003398 | EDGAR | — |
| 2025-08-06 | 0000950170-25-103990 | EDGAR | — |
356 total filings indexed. 324 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001262104 |
| Ticker | LITS |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.litestrategy.com |
| Listed | 2003-12-18 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report